共 50 条
- [1] Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 StudyBLOOD, 2018, 132Ravandi, FarhadBashey, AsadForan, James M.Stock, WendyMawad, RayaBlum, WilliamSaville, M. WayneJohnson, Chelsea M.Vanasse, K. Gary J.Ly, ThomasKantarjian, Hagop M.Bhatnagar, BhavanaTakahashi, KoichiMims, Alice S.
- [2] Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromeBLOOD, 2017, 130Uy, Geoffrey L.Godwin, JohnRettig, Michael P.Vey, NorbertFoster, MatthewArellano, Martha L.Rizzieri, David A.Topp, Max S.Huls, GerwinLowenberg, BobMartinelli, GiovanniPaolini, StefaniaCiceri, FabioCarrabba, Matteo GiovanniBallesteros-Merino, CarmenBifulco, Carlo B.Lelievre, HeleneLa Motte-Mohs, RossLi, DanerSun, JichaoJacobs, KennethSpohn, KarenLonsdale, NadiaTran, KathyBaughman, JanShannon, MicheleFox, BernardBonvini, EzioWigginton, JonDavidson-Moncada, JanDiPersio, John F.
- [3] Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) PatientsBLOOD, 2019, 134Uy, Geoffrey L.Aldoss, IbrahimFoster, Matthew C.Sallman, David A.Sweet, Kendra L.Rizzieri, David A.Sayre, Peter H.Advani, Anjali S.Emadi, AshkanWieduwilt, Matthew J.Vey, NorbertCiceri, FabioCarrabba, Matteo GiovanniMoyo, TamaraChurch, Sarah E.Rettig, Michael P.Arellano, Martha L.Godwin, John E.Lowenberg, BobHuls, GerwinRavandi, FarhadMuth, JohnTran, KathyJongen-Lavrencic, MojcaTimmeny, ErinTopp, Max S.Paolini, StefaniaGuo, KuoCurtis, TeiaZhao, JianVadakekolathu, JayakumarWigginton, Jon M.Bonvini, EzioRutella, SergioWalter, Roland B.Davidson-Moncada, Jan K.DiPersio, John F.
- [4] Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 X CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid LeukemiaBLOOD, 2018, 132Rutella, SergioChurch, Sarah E.Vadakekolathu, JayakumarViboch, ElenaSullivan, Amy H.Hood, TressaWarren, Sarah E.Cesano, AlessandraLa Motte-Mohs, RossMuth, JohnLelievre, HeleneLowenberg, BobDiPersio, John F.Davidson-Moncada, Jan K.
- [5] First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemiaCTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (03): : 429 - 435Boyiadzis, MichaelDesai, PinkalDaskalakis, NikkiDonnellan, WilliamFerrante, LucilleGoldberg, Jenna D.Grunwald, Michael R.Guttke, ChristinaLi, XiangPerez-Simon, Jose AntonioSalamero, OlgaTucker, TrevorXu, XiaoyingYang, JayPemmaraju, NaveenAlonso-Dominguez, Juan Manuel
- [6] Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)BLOOD, 2023, 142Hutchings, MartinMontesinos, PauSantoro, ArmandoHou, Hsin-AnMartinez-Sanchez, Maria PilarVives, SusanaGalimberti, SaraChen, Tsai-YunFrigeni, MarcoGarciaz, SylvainSalamero, OlgaYeh, Su-PengYee, KarenSchnetzler, GabrielBarata, TeresaSimon, SilkeHinton, HeatherKorfi, KooroshRichard, MurielKeshelava, NinoSubklewe, Marion
- [7] A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic LymphomaBLOOD, 2021, 138Murthy, Guru Subramanian GuruKearl, Tyce J.Cui, WeiguoJohnson, BryonHoffmeister, KarinSzabo, AnikoAoki, KazuhiroHarrington, Alexandra M.Carlson, KarenMichaelis, Laura C.Runaas, LyndseyAbedin, SameemDuvall, Adam S.Stock, WendyShah, Bijal D.Leonard, JessicaPratz, Keith W.Luger, Selina M.Badar, TalhaBaim, ArielleYaghoubi, ShahriarAtallah, Ehab L.
- [8] A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid LeukemiaBLOOD, 2019, 134Wei, Andrew H.Fong, Chun YewMontesinos, PauCalbacho, MariaGil, Jordi SierraPerez De Oteyza, JaimeRowe, Jacob M.Wolach, OfirOfran, YishaiMoshe, YakirSun, JichaoBaughman, JanMcNulty, EileenBonvini, EzioWigginton, Jon M.Davidson-Moncada, Jan K.
- [9] A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid LeukemiaBLOOD, 2023, 142Murthy, Guru Subramanian GuruLeonard, Jessica T.Badar, TalhaYi, Cecilia Y. AranaDuvall, Adam S.Shah, Bijal D.Baim, ArielleKearl, TyceHarrington, Alexandra M.Szabo, AnikoAtallah, Ehab L.
- [10] A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic LeukemiaBLOOD, 2023, 142Murthy, Guru Subramanian GuruShah, Bijal D.Duvall, Adam S.Leonard, Jessica T.Badar, TalhaYi, Cecilia Y. AranaKearl, TyceBaim, ArielleHarrington, Alexandra M.Szabo, AnikoAtallah, Ehab L.